跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML0123

Sigma-Aldrich

Deflazacort

≥98% (HPLC)

别名:

(11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 11β,21-dihydroxy-2′-methyl-5′βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2′-acetate, DL-458-IT, L-5458, azacort, oxazacort, pregna-1,4-diene-11β,21-diol-3,20-dione[17α,16α-d]-2′-methyloxazoline 21-acetate

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C25H31NO6
CAS号:
14484-47-0
分子量:
441.52
EC號碼:
238-483-7
MDL號碼:
MFCD00866106
分類程式碼代碼:
51111800
PubChem物質ID:
329825173
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to tan

溶解度

DMSO: ≥20 mg/mL

儲存溫度

2-8°C

SMILES 字串

CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C

InChI

1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

InChI 密鑰

FBHSPRKOSMHSIF-GRMWVWQJSA-N

基因資訊

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

相关类别

生化／生理作用

Deflazacort is an Anti-inflammatory glucocorticoid
Deflazacort is an anti-inflammatory and immunosuppressant glucocorticoid.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

David E Lebel et al.
The Journal of bone and joint surgery. American volume, 95(12), 1057-1061 (2013-06-21)
Duchenne muscular dystrophy, a progressive muscle disorder that occurs in males, causes a gradual decline in muscle strength. This progressive decline is associated with the development of scoliosis. Previous studies have shown that the use of glucocorticoids slows the progression
Walter Alberto Sifuentes Giraldo et al.
Reumatologia clinica, 8(4), 208-211 (2012-01-31)
Hypertrophic osteoarthropathy is an entity characterized by a triad of periostitis of long bones, clubbing and arthritis. Radiologically there are two patterns, one characterized by new bone formation which predominates in patients with pulmonary disease, and another by acro-osteolysis that
Luciano Merlini et al.
Muscle & nerve, 45(6), 796-802 (2012-05-15)
Corticosteroid treatment is the standard of care in Duchenne muscular dystrophy (DMD), but the optimal age to initiate treatment and dosage pattern remain a matter of discussion. We performed a long-term study of alternate-day corticosteroids in five 2- to 4-year-old
Darlene L Machado et al.
BMC research notes, 5, 435-435 (2012-08-15)
Duchenne muscular dystrophy (DMD) is a sex-linked inherited muscle disease characterized by a progressive loss in muscle strength and respiratory muscle involvement. After 12 years of age, lung function declines at a rate of 6 % to 10.7 % per
Karen Uzark et al.
Pediatrics, 130(6), e1559-e1566 (2012-11-07)
The purpose of this study was to assess health-related quality of life (QoL) in children with Duchenne muscular dystrophy (DMD), including development and field-testing of a DMD-specific module integrated with the core Pediatric Quality of Life Inventory (PedsQL). The PedsQL
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门